daniel drucker glp 1 GLP-1 medicine improves liver health independent of weight loss Canadian scientist wins Breakthrough Prize

2012;2:e134

Warnings: This product is a dietary supplement and not a medicine

Summary of efficacy and safety of currently-available obesity pharmacotherapy Tirzepatide and Emerging Approaches Besides the approval of semaglutide 2.4mg, much of the excitement in the field of obesity management also has to do with the approval of a dual GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist tirzepatide, which is currently approved for the management of T2D but has also shown promising results in the treatment of obesity in patients with and without T2D [28]

FDA materials flag compounded injectable GHK-Cu as a safety concern because human safety data are limited [8]

BlinkenbergMMathiesenHKTscherningTJnssonASvarerCHolmSet al